Nan Fung Trinity HK Ltd. Invests $5.10 Million in Immunome, Inc. $IMNM

Nan Fung Trinity HK Ltd. acquired a new position in shares of Immunome, Inc. (NASDAQ:IMNM) in the second quarter, according to its most recent disclosure with the SEC. The firm acquired 548,850 shares of the company’s stock, valued at approximately $5,104,000. Nan Fung Trinity HK Ltd. owned 0.63% of Immunome at the end of the most recent quarter.

A number of other large investors have also modified their holdings of IMNM. Teacher Retirement System of Texas boosted its stake in shares of Immunome by 49.0% in the first quarter. Teacher Retirement System of Texas now owns 17,360 shares of the company’s stock valued at $117,000 after buying an additional 5,712 shares in the last quarter. Bank of New York Mellon Corp boosted its position in shares of Immunome by 56.8% during the 1st quarter. Bank of New York Mellon Corp now owns 193,147 shares of the company’s stock worth $1,300,000 after purchasing an additional 69,944 shares in the last quarter. Alps Advisors Inc. grew its stake in shares of Immunome by 23.9% during the 1st quarter. Alps Advisors Inc. now owns 62,544 shares of the company’s stock worth $421,000 after purchasing an additional 12,074 shares during the period. Arizona State Retirement System boosted its holdings in Immunome by 66.2% during the first quarter. Arizona State Retirement System now owns 18,764 shares of the company’s stock worth $126,000 after buying an additional 7,476 shares in the last quarter. Finally, KLP Kapitalforvaltning AS grew its position in Immunome by 140.8% during the first quarter. KLP Kapitalforvaltning AS now owns 17,100 shares of the company’s stock worth $115,000 after buying an additional 10,000 shares during the period. 44.58% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on the company. Guggenheim reaffirmed a “buy” rating and issued a $25.00 price objective on shares of Immunome in a research note on Monday, August 25th. JPMorgan Chase & Co. decreased their price objective on shares of Immunome from $23.00 to $22.00 and set an “overweight” rating on the stock in a research report on Thursday, August 7th. The Goldman Sachs Group assumed coverage on shares of Immunome in a report on Monday, September 22nd. They set a “buy” rating and a $26.00 target price for the company. Craig Hallum initiated coverage on shares of Immunome in a report on Friday, September 5th. They issued a “buy” rating and a $26.00 price target on the stock. Finally, Wall Street Zen cut shares of Immunome from a “hold” rating to a “sell” rating in a research note on Saturday. Ten analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $23.20.

Immunome Stock Performance

Shares of NASDAQ IMNM opened at $17.52 on Wednesday. Immunome, Inc. has a 1 year low of $5.15 and a 1 year high of $17.87. The firm’s 50 day moving average price is $13.13 and its 200 day moving average price is $10.63. The firm has a market cap of $1.61 billion, a P/E ratio of -5.94 and a beta of 1.96.

Immunome (NASDAQ:IMNM) last released its earnings results on Thursday, November 6th. The company reported ($0.65) earnings per share for the quarter, missing the consensus estimate of ($0.57) by ($0.08). Immunome had a negative return on equity of 76.50% and a negative net margin of 1,687.08%. As a group, equities analysts predict that Immunome, Inc. will post -2.21 EPS for the current year.

Immunome Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.